Dai­ichi Sankyo con­cedes an ear­ly set­back on Duchenne MD drug, but dou­bles down on de­vel­op­ment

Two years ago, when in­ves­ti­ga­tors for Dai­ichi Sankyo gave its ex­per­i­men­tal Duchenne mus­cu­lar dy­s­tro­phy drug to the very first pa­tient in a clin­i­cal tri­al, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER